Vienna, Austria

ESTRO 2023

Session Item

Poster (Digital)
Stereotactic APBI for early-stage breast cancer: 3-year outcomes of a prospective registry
Jonathan Cantalino, USA


Stereotactic APBI for early-stage breast cancer: 3-year outcomes of a prospective registry

Jonathan Cantalino1, Monica Pernia Marin2, David D'Ambrosio3, Arica Hirsch4, Malika Danner1, Sonali Rudra1, Simeng Suy1, Sean Collins1, Dawn Matsanka5, Michael Good5, Jing Feng5, John Lamond5, Deborah Markiewicz5, Rachelle Lanciano5, Olusola Obayomi-Davies6, Brian Collins7

1Medstar Georgetown University Hospital, Department of Radiation Medicine, Washington, DC, USA; 2The George Washington University Hospital, Geriatric and Palliative Care Division, Washington, DC, USA; 3Community Medical Center, New Jersey Cyberknife, Toms River, NJ, USA; 4Advocate Lutheran General Hospital, Illinois Cyberknife, Park Ridge, IL, USA; 5Crozer Keystone Health Care Center, Philadelphia Cyberknife, Philadelphia, PA, USA; 6Wellstar Medical Group, Department of Radiation Oncology, Marietta, GA, USA; 7Tampa General Hospital, Department of Radiation Oncology, Tampa, FL, USA

Show Affiliations
Purpose or Objective

Outcomes following adjuvant accelerated partial breast irradiation (APBI) in select women with early-stage breast cancer are comparable to whole breast irradiation. Robotic stereotactic accelerated partial breast irradiation (RSAPBI) with fiducial tracking is an attractive adjuvant treatment option, but limited outcomes data are available for this approach. We report 3-year outcomes for a prospective multi-institutional registry treating select women with RSAPBI.

Material and Methods

Post-menopausal women with DCIS and Stage IA breast cancer were treated over a five-year period extending from November 2015 to November 2020 and were followed for a minimum of 24 months. Treatments were delivered with a robotic radiosurgery system. Four gold fiducials were implanted around the lumpectomy cavity prior to the start of treatment for tumor bed delineation and target tracking. The CTV was defined as the lumpectomy cavity with a uniform 5-15 mm expansion confined to the breast tissue and the PTV was defined as the CTV with a 0-5 mm uniform expansion. The PTV was prescribed 30 Gy in 5 fractions. Disease status, toxicity, and cosmetic assessments were completed at 4 weeks, 3 months, 6 months, 12 months, 18 months, 24 months and yearly intervals thereafter for five years. Cosmesis was scored per the Harvard Breast Cosmesis Scale and toxicity was graded per RTOG toxicity criteria.


Eighty-one patients (median age 68 years) with hormone receptor-positive tumors were treated over a median 9 days (range, 5-15). Sixty-eight women had invasive ductal carcinoma (84%) and thirteen had DCIS (16%). The median treated PTV was 108 cm3 (IQR 66-156) and the median prescription isodose line was 81% (IQR 79-83). The median CTV expansion was 10 mm (range 5-10) and the median PTV expansion was 3 mm (range 0-5). At a median follow up of 3 years there was one new ipsilateral breast tumor occurrence with no local, regional, or distant treatment failures. Overall survival was 95%, with no deaths due to breast cancer. Grade 1 skin toxicity was seen in two women at 3 years. No grade 2 through 4 toxicity of any kind was observed. Cosmesis at last follow-up was rated excellent for 84% and good for 15% of patients.


The 3-year outcomes of this prospective multi-institutional registry suggest that RSAPBI with fiducial tracking is a practical, effective and well-tolerated technique for the adjuvant treatment of early-stage breast cancer. Our current prospective multi-institutional registry is now enrolling elderly patients (>70 y/o) with early-stage breast cancer who decline surgery and wish to complete RSAPBI treatment alone.